Omnicomm's TrialMaster EDC solution chosen by Impax Pharmaceuticals for study in Parkinson's disease

OmniComm Systems, Inc. (OTC Bulletin Board: OMCM), one of the fastest growing companies in the EDC marketplace, today announced that Impax Pharmaceuticals, the brand division of Impax Laboratories, Inc., Hayward, CA, has selected the TrialMaster EDC solution for conducting a Phase III study in patients with Parkinson's Disease. "While managing a global multi site clinical trial there can be significant challenges in getting trial data when you want it and in the format that you need it," said Suneel Gupta, PhD, Chief Scientific Officer for Impax. "The TrialMaster EDC solution provides us with an intuitive and easy to use export tool that simplifies the process. After considering multiple different EDC solutions, we selected OmniComm Systems based on its customer driven approach and reputation for delivering unparalleled service and support. Additionally, its support of industry standards has enabled us to meet our very tight corporate timelines for this important study."

"We look forward to working with Impax to assist them in the fight to cure Parkinson's disease," remarked Stephen Johnson, COO of OmniComm Systems. "We are honored that after an extensive evaluation, OmniComm's electronic data capture solution, TrialMaster(TM), was chosen to capture and process their clinical trial data. TrialMaster(TM) will enable them to continue to make informed and strategic decisions that will be vital to their success as a company."